奈达铂联合紫杉醇新辅助化疗方案在局部晚期宫颈癌患者中的应用效果

摘要

目的 探讨奈达铂联合紫杉醇新辅助化疗方案在局部晚期宫颈癌患者中的应用效果.方法 选取2010年9月至013年3月徐州医学院附属医院收治的局部晚期宫颈癌患者60例,随机分成奈达铂组及对照组,每组30例.奈达铂组采用奈达铂联合紫杉醇新辅助化疗方案,对照组采用顺铂联合紫杉醇新辅助化疗方案,对比两组患者的疗效及不良反应.结果 奈达铂组与对照组患者短期总有效率分别为76.7％、80.0％,两组比较差异无统计学意义(x2 =0.098,P=0.754).与化疗前相比,两组患者化疗后肿瘤直径较化疗前缩小[(5.3±0.9)vs(3.2±0.6),(5.2±0.8)vs(3.3±0.7)];差异有统计学意义(P＜0.05).与对照组相比,奈达铂组患者治疗后I～Ⅱ级恶心呕吐(36.7％vs70.0％)、贫血(16.7％ vs 40.0％)、肾功能损害(10.0％vs36.7％)发生率较低,Ⅰ～Ⅱ级血小板降低(56.7％vs30％)发生率较高,差异均有统计学意义(P均＜0.05).结论 奈达铂联合紫杉醇新辅助化疗方案治疗局部晚期宫颈癌疗效与顺铂类似,但不良反应少.%Objective To explore the application efficacy of nedaplatin combined with paclitaxel in neoadjuvant chemotherapy for the ()atients with locally advanced cervical cancer.Methods Sixty patients with locally advanced cervical cancer,ever treated in our hospital from Sep 2010 to Mar 2013,were randomly divided into the nedaplatin group and the control group,30 patients in each group.Patients in the ()edaplatin group were treated by neoadjuvant chemotherapy with nedaplatin and paclitaxel,while patients in the control group were treated with cisplatin and paclitaxel.The curative effects and adverse reactions of patients between the two groups were compared.Results The short()erm total effective rates in the nedaplatin group and the control group were 76.7％ and 80.0％,respectively,with no significant difference ()etween them (x2 =0.098,P =0.754).Patients in the two groups both had significantly shorter tumor diameters after chemotherapy than ()hose before chemotherapy (5.3-± 0.9 vs 3.2 ± 0.6,5.2 ± 0.8 vs 3.3-± 0.7;P ＜ 0.05).When compared with the control group,the neda()latin group had lower incidences of stage Ⅰ ～ Ⅱ nausea and vomiting (36.7％ vs 70.0％),anemia (16.7％ vs 40.0％) and renal function damage (10.0％ vs 36.7％),but had higher incidence of stage Ⅰ ～ Ⅱ thrombocytopenia (56.7％ vs 30％),and their differences were sta()istically significant (all P ＜ 0.05).Conclusion The neoadjuvant chemotherapy with nedaplatin combined with paclitaxel may have similar curative effects as cisplatin combined with paclitaxel in the treatment of locally advanced cervical cancer,but with less adverse reactions,and it is worthy of clinical promotion.